Evidence map›Paper›PMID 23291729›Full record

Trial reportEuropean journal of heart failure2013

Double dose vs. standard dose influenza vaccination in patients with heart failure: a pilot study.

Amy Van Ermen, Matthew P Hermanson, John M Moran, Nancy K Sweitzer, Maryl R Johnson, Orly Vardeny

Registry-linked trialOpen access · bronzeAbstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in European journal of heart failure, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02787044 (INfluenza Vaccine to Effectively Stop Cardio Thoracic Events and Decompensated Heart Failure), which is not on this map. Cited by 19 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed, 4 pooled it
1.6field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02787044 phase4completednot on this mapstarted 2016, after this paper: background citation

INfluenza Vaccine to Effectively Stop Cardio Thoracic Events and Decompensated Heart Failure

TypeinterventionalSponsorBrigham and Women's HospitalRan2016 to 2020Enrolled5,388ConditionsHeart Failure, Myocardial InfarctionArmsHigh Dose Trivalent Influenza Vaccine, Standard Dose Quadrivalent Influenza Vaccine
3 · Its place in the literature

Who cites it

19 citing papers in PubMed, 4 syntheses or guidelines pooled it, 32 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Influenza vaccines for preventing cardiovascular disease.The Cochrane database of systematic reviews · 2015
    Pooled it
  5. Trial
  6. Trial
  7. Trial
  8. Trial
  9. Article
  10. Review
  11. Article
  12. Article
  13. Article
  14. Review
  15. Article
  16. Review
  17. Review
  18. Article
  19. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Amy Van ErmenSchool of Pharmacy, University of Wisconsin, Madison, WI 53705, USA.
Matthew P Hermanson
John M Moran
Nancy K Sweitzer
Maryl R Johnson
Orly Vardeny
University of Wisconsin–Madison · USUW Health University Hospital · US

Funding

Institutional Clinical and Translational Science AwardUL1TR000427 · NCATS · UNIVERSITY OF WISCONSIN-MADISON · PI DREZNER, MARC KENNETH · 2012 to 2016
$32.2M
Institutional Clinical and Translational Science Award (UW-Madison)KL2RR025012 · NCRR · UNIVERSITY OF WISCONSIN-MADISON · PI DREZNER, MARC KENNETH · 2007 to 2011
$11.1M
NCATS NIH HHS UL1 TR000427NCRR NIH HHS 1KL2RR025012-01NCRR NIH HHS KL2 RR025012
6 · The paper itself

Abstract

aimsInfluenza infection leads to increased morbidity and mortality in those with heart failure, and individuals with heart failure exhibit reduced antibody responses to influenza vaccine. We hypothesized that patients with heart failure randomized to double dose (DD) influenza vaccine will mount more vigorous humoral immune responses compared with those given standard dose (SD) vaccine. METHODS AND

resultsWe randomized 28 heart failure patients to DD (30 μg/strain) or SD (15 μg/strain) influenza vaccine. We assessed antibody production by haemagglutination inhibition assay (reported as log haemagglutination units) prior to, at 2-4 weeks and at 4-6 months following vaccination. Baseline antibody titres between DD (n = 12, mean age 64 ± 10 years) and SD (n = 16, mean age 63 ± 9 years) did not differ significantly. At 2-4 weeks, DD haemagglutination unit changes were significantly higher than those of SD (3.3 vs. 1.6 for A/H3N2, P < 0.001; 1.9 and 1.1 for A/H1N1, P = 0.009; and 1.7 and 1 for B-type, P = 0.02). At 4-6 weeks, there were no differences in titres in any of the virus types between treatment groups and, although titres decreased, levels remained above the seroprotective threshold.

conclusionsHigher influenza vaccine doses may elicit increased antibody-mediated responses in patients with heart failure; further studies should assess whether clinical outcomes are improved with this strategy.

Indexed as

AgedAntibodies, ViralDose-Response Relationship, ImmunologicDouble-Blind MethodFemaleHeart FailureHemagglutination Inhibition TestsHumansImmunity, HumoralInfluenza A Virus, H1N1 SubtypeInfluenza A Virus, H3N2 SubtypeInfluenza B virusInfluenza, HumanInfluenza VaccinesMaleMiddle AgedAntibodies, ViralInfluenza Vaccines

Identifiers

PMID23291729
PMCPMC3631764
OpenAlexW2012603277

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.